CEO Jasbir Seehra outlined the company’s development priorities and partnership plans during a presentation at Oppenheimer’s ...
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...
Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE® ...
Pratteln, Switzerland, February 27, 2026 - Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE (va ...
Concurrent with Mr. Newton joining Keros’ Board of Directors, the Company also announced that Carl Gordon, Ph.D., CFA, will be stepping down as a director of the Company, effective March 9, 2026.
Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
West Virginia lawmakers want health insurance companies to pay for scalp cooling treatment for cancer patients in an effort ...
Background Ocular chronic graft versus host disease (oGVHD) seriously affects ocular surface, which often results in corneal ...
Researchers identified a molecular pathway that can limit muscle repair, a finding that may guide future muscular dystrophy treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results